Logo image of ADCT

ADC THERAPEUTICS SA (ADCT) Stock Fundamental Analysis

NYSE:ADCT - New York Stock Exchange, Inc. - CH0499880968 - Common Stock

1.7  -0.06 (-3.41%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ADCT. ADCT was compared to 572 industry peers in the Biotechnology industry. Both the profitability and financial health of ADCT have multiple concerns. ADCT is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ADCT has reported negative net income.
In the past year ADCT has reported a negative cash flow from operations.
In the past 5 years ADCT always reported negative net income.
In the past 5 years ADCT always reported negative operating cash flow.
ADCT Yearly Net Income VS EBIT VS OCF VS FCFADCT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M -200M -250M

1.2 Ratios

ADCT's Return On Assets of -105.18% is on the low side compared to the rest of the industry. ADCT is outperformed by 77.17% of its industry peers.
Industry RankSector Rank
ROA -105.18%
ROE N/A
ROIC N/A
ROA(3y)-44.77%
ROA(5y)-53.37%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ADCT Yearly ROA, ROE, ROICADCT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 100 -100

1.3 Margins

ADCT has a Gross Margin of 94.24%. This is amongst the best in the industry. ADCT outperforms 95.22% of its industry peers.
ADCT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 94.24%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADCT Yearly Profit, Operating, Gross MarginsADCT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K -8K -10K

More info and screens

2

2. Health

2.1 Basic Checks

ADCT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ADCT has been increased compared to 1 year ago.
Compared to 5 years ago, ADCT has more shares outstanding
ADCT has a worse debt/assets ratio than last year.
ADCT Yearly Shares OutstandingADCT Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
ADCT Yearly Total Debt VS Total AssetsADCT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

ADCT has an Altman-Z score of -6.90. This is a bad value and indicates that ADCT is not financially healthy and even has some risk of bankruptcy.
ADCT has a Altman-Z score of -6.90. This is in the lower half of the industry: ADCT underperforms 68.50% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -6.9
ROIC/WACCN/A
WACC6.45%
ADCT Yearly LT Debt VS Equity VS FCFADCT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M

2.3 Liquidity

ADCT has a Current Ratio of 4.92. This indicates that ADCT is financially healthy and has no problem in meeting its short term obligations.
ADCT has a Current ratio (4.92) which is in line with its industry peers.
ADCT has a Quick Ratio of 4.68. This indicates that ADCT is financially healthy and has no problem in meeting its short term obligations.
ADCT has a Quick ratio (4.68) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.92
Quick Ratio 4.68
ADCT Yearly Current Assets VS Current LiabilitesADCT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

6

3. Growth

3.1 Past

ADCT shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -8.64%.
Looking at the last year, ADCT shows a small growth in Revenue. The Revenue has grown by 0.75% in the last year.
Measured over the past years, ADCT shows a very strong growth in Revenue. The Revenue has been growing by 129.19% on average per year.
EPS 1Y (TTM)-8.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.59%
Revenue 1Y (TTM)0.75%
Revenue growth 3YN/A
Revenue growth 5Y129.19%
Sales Q2Q%27.4%

3.2 Future

Based on estimates for the next years, ADCT will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.08% on average per year.
ADCT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 30.34% yearly.
EPS Next Y40.57%
EPS Next 2Y20.29%
EPS Next 3Y17.08%
EPS Next 5YN/A
Revenue Next Year6.48%
Revenue Next 2Y9.1%
Revenue Next 3Y18.23%
Revenue Next 5Y30.34%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ADCT Yearly Revenue VS EstimatesADCT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M 400M
ADCT Yearly EPS VS EstimatesADCT Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ADCT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ADCT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ADCT Price Earnings VS Forward Price EarningsADCT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADCT Per share dataADCT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as ADCT's earnings are expected to grow with 17.08% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.29%
EPS Next 3Y17.08%

More info and screens

0

5. Dividend

5.1 Amount

ADCT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADC THERAPEUTICS SA

NYSE:ADCT (1/22/2025, 10:39:06 AM)

1.7

-0.06 (-3.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)N/A N/A
Inst Owners54.72%
Inst Owner Change0%
Ins Owners4.45%
Ins Owner Change-0.87%
Market Cap164.37M
Analysts84.62
Price Target8.57 (404.12%)
Short Float %6.73%
Short Ratio4.76
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)7.16%
Min EPS beat(2)-4.24%
Max EPS beat(2)18.56%
EPS beat(4)2
Avg EPS beat(4)-21.31%
Min EPS beat(4)-100.76%
Max EPS beat(4)18.56%
EPS beat(8)3
Avg EPS beat(8)-13.77%
EPS beat(12)6
Avg EPS beat(12)-5.28%
EPS beat(16)8
Avg EPS beat(16)-11.91%
Revenue beat(2)0
Avg Revenue beat(2)-5.57%
Min Revenue beat(2)-9.2%
Max Revenue beat(2)-1.95%
Revenue beat(4)1
Avg Revenue beat(4)-1.49%
Min Revenue beat(4)-9.2%
Max Revenue beat(4)7.4%
Revenue beat(8)2
Avg Revenue beat(8)-8.69%
Revenue beat(12)5
Avg Revenue beat(12)2.59%
Revenue beat(16)7
Avg Revenue beat(16)-1.79%
PT rev (1m)0%
PT rev (3m)-14.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)11.29%
EPS NY rev (1m)0%
EPS NY rev (3m)62.88%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-7.7%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.33
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.39
EYN/A
EPS(NY)-1.62
Fwd EYN/A
FCF(TTM)-1.41
FCFYN/A
OCF(TTM)-1.4
OCFYN/A
SpS1.28
BVpS-1.78
TBVpS-1.78
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -105.18%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 94.24%
FCFM N/A
ROA(3y)-44.77%
ROA(5y)-53.37%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr -1452.63%
Cap/Sales 0.89%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.92
Quick Ratio 4.68
Altman-Z -6.9
F-Score3
WACC6.45%
ROIC/WACCN/A
Cap/Depr(3y)204.08%
Cap/Depr(5y)174.65%
Cap/Sales(3y)8.18%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.59%
EPS Next Y40.57%
EPS Next 2Y20.29%
EPS Next 3Y17.08%
EPS Next 5YN/A
Revenue 1Y (TTM)0.75%
Revenue growth 3YN/A
Revenue growth 5Y129.19%
Sales Q2Q%27.4%
Revenue Next Year6.48%
Revenue Next 2Y9.1%
Revenue Next 3Y18.23%
Revenue Next 5Y30.34%
EBIT growth 1Y-93.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year18.49%
EBIT Next 3Y1.99%
EBIT Next 5YN/A
FCF growth 1Y8.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y7.7%
OCF growth 3YN/A
OCF growth 5YN/A